Boehringer Ingelheim Vetmedica has secured the pharma licensing rights for the technology platform Artilysin from Lysando.

Artilysin developed by the research & development company Lysando, has arrived in the pharmaceutical industry.

The company is hopeful to receive significant momentum and solutions from this new substance class for the problem of multi-resistant bacteria, which also is an increasing threat to the animal world.

Artilysin are proteins that, through a physical mechanism, selectively eliminate pathogenic, multi-resistant and persisting bacteria.

By way of license, Boehringer Ingelheim Vetmedica is taking advantage of the possibilities presented by this technology.

The scope of applications for Artilysin's spans from human and animal medicine to the food industry and the area of hygiene.

For further deal information visit Current Agreements (subscription required)

Related

Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary

Read: Big pharma deal news- latest deal news for top 50 pharma / big pharma companies

Report: Practical Guide to Finding Partners

Report: Partnering Deals and Alliances with Big Pharma

Report: Partnering Deals and Alliances with Boehringer Ingelheim

Related reports: Bigpharma Partnering Yearbook 2013

View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more